Development

Latest News

blood stream
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim

November 25th 2023

A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.

Image credit: Aliaksandr Marko | stock.adobe.com
Confusion Persists Around the Interchangeability Designation for Biosimilars

November 23rd 2023

injectable pens
BioRationality: FDA Publishes Results of First Meta-Analysis to Conclude All Biosimilars Are Interchangeable

November 20th 2023

syringe with GBW and CFB logos | Image credit: Davizro Photography | stock.adobe.com
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe

November 16th 2023

Eye on Pharma banner
Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate

November 8th 2023

More News

© 2023 MJH Life Sciences

All rights reserved.